US9066695B2
(en)
|
1998-04-30 |
2015-06-30 |
Abbott Diabetes Care Inc. |
Analyte monitoring device and methods of use
|
US6175752B1
(en)
|
1998-04-30 |
2001-01-16 |
Therasense, Inc. |
Analyte monitoring device and methods of use
|
US8480580B2
(en)
|
1998-04-30 |
2013-07-09 |
Abbott Diabetes Care Inc. |
Analyte monitoring device and methods of use
|
US8346337B2
(en)
|
1998-04-30 |
2013-01-01 |
Abbott Diabetes Care Inc. |
Analyte monitoring device and methods of use
|
US6949816B2
(en)
|
2003-04-21 |
2005-09-27 |
Motorola, Inc. |
Semiconductor component having first surface area for electrically coupling to a semiconductor chip and second surface area for electrically coupling to a substrate, and method of manufacturing same
|
US8974386B2
(en)
|
1998-04-30 |
2015-03-10 |
Abbott Diabetes Care Inc. |
Analyte monitoring device and methods of use
|
US8688188B2
(en)
|
1998-04-30 |
2014-04-01 |
Abbott Diabetes Care Inc. |
Analyte monitoring device and methods of use
|
US8465425B2
(en)
|
1998-04-30 |
2013-06-18 |
Abbott Diabetes Care Inc. |
Analyte monitoring device and methods of use
|
US6560471B1
(en)
|
2001-01-02 |
2003-05-06 |
Therasense, Inc. |
Analyte monitoring device and methods of use
|
DE10114178A1
(en)
*
|
2001-03-23 |
2002-10-10 |
Aventis Pharma Gmbh |
Zinc-free and low-zinc insulin preparations with improved stability
|
AU2002309528A1
(en)
|
2001-04-02 |
2002-10-15 |
Therasense, Inc. |
Blood glucose tracking apparatus and methods
|
ATE382057T1
(en)
|
2001-06-28 |
2008-01-15 |
Novo Nordisk As |
STABLE FORMULATION OF MODIFIED GLP-1
|
US6737401B2
(en)
|
2001-06-28 |
2004-05-18 |
Metronic Minimed, Inc. |
Methods of evaluating protein formulation stability and surfactant-stabilized insulin formulations derived therefrom
|
DE10227232A1
(en)
*
|
2002-06-18 |
2004-01-15 |
Aventis Pharma Deutschland Gmbh |
Sour insulin preparations with improved stability
|
ITMI20021684A1
(en)
*
|
2002-07-29 |
2004-01-29 |
Therapicon Srl |
PHARMACEUTICAL COMPOSITION OF NASAL PEPTIDE
|
US20090035260A1
(en)
*
|
2002-07-29 |
2009-02-05 |
Therapicon Srl |
Enhanced nasal composition of active peptide
|
AU2003303597A1
(en)
|
2002-12-31 |
2004-07-29 |
Therasense, Inc. |
Continuous glucose monitoring system and methods of use
|
CA2820537C
(en)
|
2003-04-23 |
2015-10-20 |
Valeritas, Inc. |
Hydraulically actuated pump for fluid administration
|
BRPI0410972C1
(en)
|
2003-06-03 |
2021-05-25 |
Novo Nordisk As |
method for increasing the shelf life of a pharmaceutical composition, pharmaceutical composition, and method for treating hyperglycemia
|
PL1633391T3
(en)
|
2003-06-03 |
2012-03-30 |
Novo Nordisk As |
Stabilized pharmaceutical peptide compositions
|
US8066639B2
(en)
|
2003-06-10 |
2011-11-29 |
Abbott Diabetes Care Inc. |
Glucose measuring device for use in personal area network
|
ES2660320T3
(en)
|
2003-11-20 |
2018-03-21 |
Novo Nordisk A/S |
Peptide formulations containing propylene glycol that are optimal for production and for use in injection devices
|
ITMI20040235A1
(en)
*
|
2004-02-13 |
2004-05-13 |
Therapicon Srl |
PHARMACEUTICAL PREPARATION FOR THE ORAL CABLE
|
WO2005089103A2
(en)
|
2004-02-17 |
2005-09-29 |
Therasense, Inc. |
Method and system for providing data communication in continuous glucose monitoring and management system
|
US9089636B2
(en)
|
2004-07-02 |
2015-07-28 |
Valeritas, Inc. |
Methods and devices for delivering GLP-1 and uses thereof
|
EP1773878B1
(en)
|
2004-07-19 |
2015-03-04 |
Biocon Limited |
Insulin-oligomer conjugates, formulations and uses thereof
|
US8710181B2
(en)
|
2004-08-31 |
2014-04-29 |
Novo Nordisk A/S |
Use of tris(hydroxymethyl) aminomethane for the stabilization of peptides, polypeptides and proteins
|
RU2413530C9
(en)
|
2004-11-12 |
2021-05-18 |
Ново Нордиск А/С |
Stable preparations of insulin peptides
|
JP2008528509A
(en)
*
|
2005-01-21 |
2008-07-31 |
アルザ コーポレイション |
Therapeutic peptide formulation for coating microneedles with improved stability comprising at least one counter ion
|
US8112240B2
(en)
|
2005-04-29 |
2012-02-07 |
Abbott Diabetes Care Inc. |
Method and apparatus for providing leak detection in data monitoring and management systems
|
US20090060861A1
(en)
*
|
2005-05-25 |
2009-03-05 |
Novo Nordisk A/S |
Stabilized Polypeptide Formulations
|
JP5235661B2
(en)
*
|
2005-05-25 |
2013-07-10 |
ノボ・ノルデイスク・エー/エス |
Stabilized polypeptide preparation
|
CA2915270C
(en)
|
2005-08-05 |
2017-07-11 |
Amgen Inc. |
Stable aqueous protein or antibody pharmaceutical formulations and their preparation
|
US7766829B2
(en)
|
2005-11-04 |
2010-08-03 |
Abbott Diabetes Care Inc. |
Method and system for providing basal profile modification in analyte monitoring and management systems
|
US20070191271A1
(en)
*
|
2006-02-10 |
2007-08-16 |
Dow Pharmaceutical Sciences |
Method for stabilizing polypeptides lacking methionine
|
AU2007233231B2
(en)
|
2006-03-30 |
2011-02-24 |
Mannkind Corporation |
Multi-cartridge fluid delivery device
|
US7620438B2
(en)
|
2006-03-31 |
2009-11-17 |
Abbott Diabetes Care Inc. |
Method and system for powering an electronic device
|
US8226891B2
(en)
|
2006-03-31 |
2012-07-24 |
Abbott Diabetes Care Inc. |
Analyte monitoring devices and methods therefor
|
WO2007143225A2
(en)
|
2006-06-07 |
2007-12-13 |
Abbott Diabetes Care, Inc. |
Analyte monitoring system and method
|
GB0700523D0
(en)
*
|
2007-01-11 |
2007-02-21 |
Insense Ltd |
The Stabilisation Of Proteins
|
US8732188B2
(en)
|
2007-02-18 |
2014-05-20 |
Abbott Diabetes Care Inc. |
Method and system for providing contextual based medication dosage determination
|
US8930203B2
(en)
|
2007-02-18 |
2015-01-06 |
Abbott Diabetes Care Inc. |
Multi-function analyte test device and methods therefor
|
US8123686B2
(en)
|
2007-03-01 |
2012-02-28 |
Abbott Diabetes Care Inc. |
Method and apparatus for providing rolling data in communication systems
|
US7928850B2
(en)
|
2007-05-08 |
2011-04-19 |
Abbott Diabetes Care Inc. |
Analyte monitoring system and methods
|
US8665091B2
(en)
|
2007-05-08 |
2014-03-04 |
Abbott Diabetes Care Inc. |
Method and device for determining elapsed sensor life
|
US8461985B2
(en)
|
2007-05-08 |
2013-06-11 |
Abbott Diabetes Care Inc. |
Analyte monitoring system and methods
|
US8456301B2
(en)
|
2007-05-08 |
2013-06-04 |
Abbott Diabetes Care Inc. |
Analyte monitoring system and methods
|
UA114700C2
(en)
|
2007-10-16 |
2017-07-25 |
Біокон Лімітед |
SOLID PHARMACEUTICAL FORM FOR ORAL APPLICATION AND MANUFACTURING PROCESS
|
WO2009100383A2
(en)
|
2008-02-07 |
2009-08-13 |
University Of Washington |
Circumferential aerosol device
|
MX2010009850A
(en)
|
2008-03-18 |
2010-09-30 |
Novo Nordisk As |
Protease stabilized, acylated insulin analogues.
|
TWI451876B
(en)
*
|
2008-06-13 |
2014-09-11 |
Lilly Co Eli |
Pegylated insulin lispro compounds
|
PH12015501579A1
(en)
|
2008-08-15 |
2016-02-22 |
Ironwood Pharmaceuticals Inc |
Stable solid formulation of a gc-c receptor agonist polypeptide suitable for oral administration
|
PT3228320T
(en)
|
2008-10-17 |
2020-03-26 |
Sanofi Aventis Deutschland |
Combination of an insulin and a glp-1 agonist
|
US8103456B2
(en)
|
2009-01-29 |
2012-01-24 |
Abbott Diabetes Care Inc. |
Method and device for early signal attenuation detection using blood glucose measurements
|
US9226701B2
(en)
|
2009-04-28 |
2016-01-05 |
Abbott Diabetes Care Inc. |
Error detection in critical repeating data in a wireless sensor system
|
US9184490B2
(en)
|
2009-05-29 |
2015-11-10 |
Abbott Diabetes Care Inc. |
Medical device antenna systems having external antenna configurations
|
PT2340033E
(en)
*
|
2009-06-26 |
2014-02-04 |
Novo Nordisk As |
Preparation comprising insulin, nicotinamide and arginine
|
US20110027229A1
(en)
|
2009-07-31 |
2011-02-03 |
Medtronic, Inc. |
Continuous subcutaneous administration of interferon-alpha to hepatitis c infected patients
|
US8748573B2
(en)
|
2009-08-06 |
2014-06-10 |
Ironwood Pharmaceuticals, Inc. |
Formulations comprising linaclotide
|
WO2011026148A1
(en)
|
2009-08-31 |
2011-03-03 |
Abbott Diabetes Care Inc. |
Analyte monitoring system and methods for managing power and noise
|
EP2473098A4
(en)
|
2009-08-31 |
2014-04-09 |
Abbott Diabetes Care Inc |
Analyte signal processing device and methods
|
EP2482720A4
(en)
|
2009-09-29 |
2014-04-23 |
Abbott Diabetes Care Inc |
Method and apparatus for providing notification function in analyte monitoring systems
|
MY180661A
(en)
|
2009-11-13 |
2020-12-04 |
Sanofi Aventis Deutschland |
Pharmaceutical composition comprising a glp-1 agonist, an insulin and methionine
|
AU2010317994B2
(en)
|
2009-11-13 |
2014-03-06 |
Sanofi-Aventis Deutschland Gmbh |
Pharmaceutical composition comprising a GLP-1 agonist and methionine
|
US20110152820A1
(en)
*
|
2009-12-22 |
2011-06-23 |
Medtronic Minimed, Inc. |
Barrier coatings for fluids contacting medical devices
|
WO2011103311A2
(en)
|
2010-02-17 |
2011-08-25 |
Ironwood Pharmaceuticals, Inc |
Treatments for gastrointestinal disorders
|
LT2603232T
(en)
|
2010-08-11 |
2020-01-27 |
Ironwood Pharmaceuticals, Inc. |
Stable formulations of linaclotide
|
US20140148384A1
(en)
|
2010-08-30 |
2014-05-29 |
Sanofi-Aventis Deutschland Gmbh |
Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
|
CA3111516C
(en)
|
2011-03-03 |
2023-05-23 |
Impel Neuropharma, Inc. |
Nasal drug delivery device
|
WO2012154859A1
(en)
|
2011-05-09 |
2012-11-15 |
Impel Neuropharma Inc. |
Nozzles for nasal drug delivery
|
US9821032B2
(en)
|
2011-05-13 |
2017-11-21 |
Sanofi-Aventis Deutschland Gmbh |
Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
|
CA2846230A1
(en)
|
2011-08-17 |
2013-02-21 |
Ironwood Pharmaceuticals, Inc. |
Treatments for gastrointestinal disorders
|
BR112014004726A2
(en)
|
2011-08-29 |
2017-04-04 |
Sanofi Aventis Deutschland |
pharmaceutical combination for use in glycemic control in type 2 diabetes patients
|
AR087744A1
(en)
|
2011-09-01 |
2014-04-16 |
Sanofi Aventis Deutschland |
PHARMACEUTICAL COMPOSITION FOR USE IN THE TREATMENT OF A NEURODEGENERATIVE DISEASE
|
AU2012335830B2
(en)
|
2011-11-07 |
2017-05-04 |
Abbott Diabetes Care Inc. |
Analyte monitoring device and methods
|
WO2013158276A1
(en)
*
|
2012-04-20 |
2013-10-24 |
Children's Hospital Medical Center |
Antibody binding microbial heparin binding motif to retard or prevent microbial biofilm formation on implanted medical devices
|
US9623179B2
(en)
|
2012-08-30 |
2017-04-18 |
Medtronic Minimed, Inc. |
Safeguarding techniques for a closed-loop insulin infusion system
|
US10496797B2
(en)
|
2012-08-30 |
2019-12-03 |
Medtronic Minimed, Inc. |
Blood glucose validation for a closed-loop operating mode of an insulin infusion system
|
US20140066884A1
(en)
|
2012-08-30 |
2014-03-06 |
Medtronic Minimed, Inc. |
Sensor model supervisor for a closed-loop insulin infusion system
|
US10130767B2
(en)
|
2012-08-30 |
2018-11-20 |
Medtronic Minimed, Inc. |
Sensor model supervisor for a closed-loop insulin infusion system
|
US9662445B2
(en)
|
2012-08-30 |
2017-05-30 |
Medtronic Minimed, Inc. |
Regulating entry into a closed-loop operating mode of an insulin infusion system
|
US9878096B2
(en)
|
2012-08-30 |
2018-01-30 |
Medtronic Minimed, Inc. |
Generation of target glucose values for a closed-loop operating mode of an insulin infusion system
|
US9849239B2
(en)
|
2012-08-30 |
2017-12-26 |
Medtronic Minimed, Inc. |
Generation and application of an insulin limit for a closed-loop operating mode of an insulin infusion system
|
US9968306B2
(en)
|
2012-09-17 |
2018-05-15 |
Abbott Diabetes Care Inc. |
Methods and apparatuses for providing adverse condition notification with enhanced wireless communication range in analyte monitoring systems
|
KR102205512B1
(en)
|
2012-11-13 |
2021-01-20 |
아도시아 |
Quick-acting insulin formulation including a substituted anionic compound
|
NZ707160A
(en)
|
2012-12-19 |
2016-08-26 |
Wockhardt Ltd |
A stable aqueous composition comprising human insulin or an analogue or derivative thereof
|
WO2014102623A1
(en)
|
2012-12-26 |
2014-07-03 |
Wockhardt Limited |
Pharmaceutical composition
|
US10537692B2
(en)
|
2013-04-28 |
2020-01-21 |
Impel Neuropharma, Inc. |
Medical unit dose container
|
EP3229828B1
(en)
|
2014-12-12 |
2023-04-05 |
Sanofi-Aventis Deutschland GmbH |
Insulin glargine/lixisenatide fixed ratio formulation
|
WO2016137569A1
(en)
*
|
2015-02-25 |
2016-09-01 |
Dance Biopharm, Inc. |
Liquid insulin formulations and methods relating thereto
|
TWI748945B
(en)
|
2015-03-13 |
2021-12-11 |
德商賽諾菲阿凡提斯德意志有限公司 |
Treatment type 2 diabetes mellitus patients
|
TW201705975A
(en)
|
2015-03-18 |
2017-02-16 |
賽諾菲阿凡提斯德意志有限公司 |
Treatment of type 2 diabetes mellitus patients
|
KR20180052662A
(en)
|
2015-09-10 |
2018-05-18 |
임펠 뉴로파마 인코포레이티드 |
In-line nose delivery device
|
WO2018109162A1
(en)
|
2016-12-16 |
2018-06-21 |
Novo Nordisk A/S |
Insulin containing pharmaceutical compositions
|
PL3474820T3
(en)
|
2017-08-24 |
2024-05-13 |
Novo Nordisk A/S |
Glp-1 compositions and uses thereof
|
EP3713628A4
(en)
|
2017-11-21 |
2021-08-18 |
Impel Neuropharma Inc. |
Intranasal device with dip tube
|
CA3081680A1
(en)
|
2017-11-21 |
2019-05-31 |
Impel Neuropharma, Inc. |
Intranasal device with inlet interface
|
CN111936140A
(en)
|
2018-01-05 |
2020-11-13 |
英倍尔药业股份有限公司 |
Intranasal delivery of dihydroergotamine through precision nasal device
|
EP3735223A4
(en)
|
2018-01-05 |
2021-10-13 |
Impel Neuropharma Inc. |
Intranasal delivery of olanzapine by precision olfactory device
|
EP3823607A4
(en)
|
2018-07-19 |
2022-04-06 |
Impel NeuroPharma Inc. |
Respiratory tract delivery of levodopa and dopa decarboxylase inhibitor for treatment of parkinson's disease
|
US11759585B2
(en)
|
2019-01-03 |
2023-09-19 |
Impel Pharmaceuticals Inc. |
Nasal drug delivery device with detachable nozzle
|
WO2020236658A1
(en)
|
2019-05-17 |
2020-11-26 |
Impel Neuropharma, Inc. |
Single-use nasal delivery device
|
CA3165359A1
(en)
|
2020-02-18 |
2021-07-22 |
Dorthe Kot Engelund |
Glp-1 compositions and uses thereof
|